Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for HCC
NCT03510871Phase 2Completed
- Sponsor
- National Health Research Institutes
- Start
- Feb 2019
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in hepatocellular carcinoma (HCC), sponsored by National Health Research Institutes. Started Feb 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03510871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510871.